[Frontiers in Bioscience S2, 504-514, January 1, 2010]

Chemoattractants and receptors in Alzheimer's disease

Lingfei Ruan1, Yan Kong1, Ji Ming Wang2, Yingying Le1

1Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences; Graduate School of the Chinese Academy of Sciences, Shanghai, China. 2Laboratory of Molecular Immunoregulation, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, Maryland, USA

TABLE OF CONTENTS

1. Abstract
2. Introduction
3. The role of classical chemoattractant receptors in AD
4. Chemokines and their receptors in AD
4.1. CC chemokines and receptors in AD
4.1.1. CC chemokines in AD
4.1.1.1. CCL2
4.1.1.2. CCL3 and CCL4
4.1.1.3. CCL5
4.1.1.4. Other CC chemokines
4.1.2. CC chemokine receptors in AD
4.2. CXC chemokines and receptors in AD
4.2.1. CXCL1, CXCL2, CXCL8 and CXCR2 in AD
4.2.2. CXCL10 and CXCR3 in AD
4.3.3. CXCL12 and CXCR4 in AD
4.3. CX3CL1 and CX3CR1 in AD
5. Perspectives
6. Acknowledgements
7. References

1. ABSTRACT

Chemoattractants, including classical chemoattractants and chemokines, are mediators of leukocyte trafficking in physiological immunosurveillance as well as recruitment of leukocyte to the sites of inflammation and injury. Besides their well-established role in the immune system, recent researches have demonstrated that chemoattractants and their receptors are also involved in brain development and in the maintenance of normal brain homeostasis. Evidence is emerging that chemoattractants and their receptors play important roles in neuroinflammation, neuronal death and hence neurodegenerative diseases. In this review, we summarize recent progress regarding the involvement of chemoattractants and their receptors in Alzheimer's disease and their potential as therapeutic targets.